PT - JOURNAL ARTICLE AU - Nicole A. Doria-Rose AU - Xiaoying Shen AU - Stephen D Schmidt AU - Sijy O’Dell AU - Charlene McDanal AU - Wenhong Feng AU - Jin Tong AU - Amanda Eaton AU - Maha Maglinao AU - Haili Tang AU - Kelly E. Manning AU - Venkata-Viswanadh Edara AU - Lilin Lai AU - Madison Ellis AU - Kathryn Moore AU - Katharine Floyd AU - Stephanie L. Foster AU - Robert L. Atmar AU - Kirsten E. Lyke AU - Tongqing Zhou AU - Lingshu Wang AU - Yi Zhang AU - Martin R Gaudinski AU - Walker P Black AU - Ingelise Gordon AU - Mercy Guech AU - Julie E Ledgerwood AU - John N Misasi AU - Alicia Widge AU - Paul C. Roberts AU - John Beigel AU - Bette Korber AU - Rolando Pajon AU - John R. Mascola AU - Mehul S. Suthar AU - David C. Montefiori TI - Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization AID - 10.1101/2021.12.15.21267805 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.15.21267805 4099 - http://medrxiv.org/content/early/2021/12/20/2021.12.15.21267805.short 4100 - http://medrxiv.org/content/early/2021/12/20/2021.12.15.21267805.full AB - The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neutralizing activity against Omicron and compared to neutralization titers against D614G and Beta in live virus and pseudovirus assays. Omicron was 41-84-fold less sensitive to neutralization than D614G and 5.3-7.4-fold less sensitive than Beta when assayed with serum samples obtained 4 weeks after 2 standard inoculations with 100 µg mRNA-1273. A 50 µg boost increased Omicron neutralization titers and may substantially reduce the risk of symptomatic vaccine breakthrough infections.Competing Interest StatementM Maglinao and R Pajon are employees of Moderna, Inc.Funding StatementNIH 75N93019C00050 (DCM, XS), NIH U19 AI142790 (BK), Moderna, Inc., and Intramural Research Program of the Vaccine Research Center, NIAID, NIH (to NDR, SDS, SOD, YZ, MRG, WPB, IG, MG, JEL, and JRM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Duke University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors